Mitzie-Ann Davis, MD
Gynecologic Oncology · Fayetteville, GANPI 1740473735
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.4% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2022 at $4,470 and has fallen 72.5% since, to $1,229 in 2025.
Across 235 payments — averaging $51.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Merck$840
- Eisai Inc.$802
- AstraZeneca$675
- Pfizer$375
- Seagen Inc.$321
- plus $2K from 25 others
Across 4 payments — averaging $7650.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$18K
- Tesaro, Inc.$12K
What the payments were for
- Travel & lodging$3,80031%
- Food & beverage$5,67247%
- Education$2,14418%
- Gifts$4724%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 34 | $7,418 |
| Merck | 37 | $840 |
| Eisai Inc. | 32 | $802 |
| AstraZeneca | 30 | $675 |
| Pfizer | 17 | $375 |
| Seagen Inc. | 15 | $321 |
| Tesaro, Inc. | 12 | $284 |
| Clovis Oncology, Inc. | 11 | $276 |
| GSK | 14 | $269 |
| Mimedx Group, Inc. | 1 | $125 |
| Dysis Medical, Inc. | 1 | $101 |
| Daiichi Sankyo Inc. | 3 | $85 |
| AbbVie | 3 | $62 |
| Vertex | 3 | $59 |
| Coherus Oncology, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $42 |
| Myriad Genetic Laboratories, Inc. | 2 | $34 |
| Hologic Sales And Service, LLC | 2 | $31 |
| Baxter Healthcare | 2 | $30 |
| Immunogen, Inc. | 1 | $25 |
| Coopersurgical, Inc. | 1 | $23 |
| Integra Lifesciences Corporation | 1 | $22 |
| Amgen | 1 | $20 |
| Tempus AI, Inc | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| LSI Solutions Inc | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,617
- DAVINCI XI$2,000
- Rubraca$125
- DYSIS Ultra 2.0$101
- DYSIS v3 Digital Coploscope$101
- DYSIS VIEW$101
How this compares
$12,088 in reported general payments places this provider in the 80th percentile of 49 gynecologic oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 16 | $349,841 |
| Megestrol Acetate | 26 | $1,914 |
| Ondansetron Hcl | 95 | $648 |
| Dexamethasone | 25 | $562 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 110 | $504 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 26 | $291 |
| Ibuprofen | 60 | $218 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 23 | $181 |
| Gabapentin | 17 | $110 |
| Neomycin Sulfate | 14 | $59 |
| Levothyroxine Sodium | 17 | $43 |
| Metronidazole | 19 | $22 |
| Cyclobenzaprine Hcl | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $802 | $349,84116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 gynecologic oncology providers in Georgia.
Other gynecologic oncology in Fayetteville
- James BurkeSavannah$276K
- Benedict BenignoAtlanta$273K
- Sharad GhamandeAugusta$214K
- Ruchi GargNewnan$125K
- Adam PyrzakAtlanta$116K
- Gerald FeuerAtlanta$102K
- Margarett EllisonMoultrie$81K
- Vijaya GalicGainesville$35K
- Guilherme CantuariaAtlanta$13K
- Cyril SpannAtlanta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.